author-photo

Arpit Rao

University of Minnesota

23

Papers

76

Citations

Citation Trend

Filter By

Papers (18) Sort By

Journal Conference Others

Lenvatinib plus pembrolizumab in patients with either treatment-naive or previously treated metastatic renal cell carcinoma (Study 111/KEYNOTE-146): a phase 1b/2 study.

2021 Lancet Oncology
Show All
- Source
- Cite
- Save
Citations (5)
CASPAR (Alliance A031902): A randomized, phase III trial of enzalutamide (ENZ) with rucaparib (RUCA)/placebo (PBO) as a novel therapy in first-line metastatic castration-resistant prostate cancer (mCRPC).

2021 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (2)
Telehealth: Reducing or increasing cancer care disparities?

2021 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (0)
Association of ATM mutations in metastatic prostate cancer with differential genomic alteration profiles from homologous recombination deficient and proficient tumors.

2021 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (0)
Characterization of microsatellite instability (dMMR/MSI-H) and mutational landscape in a large contemporary cohort of upper tract urothelial cancer (UTUC) patients.

2021 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (1)
Rapidly evolving treatment paradigm and considerations for sequencing therapies in metastatic prostate cancer—a narrative review

2021 Translational Andrology and Urology
- Smitha Sagaram
- Arpit Rao
Show All
- Source
- Cite
- Save
Citations (0)
A phase (Ph) 1b/2 study of ribociclib (R) in combination with docetaxel (D) plus prednisone (P) in metastatic castration-resistant prostate cancer (mCRPC).

2021 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (0)
Abstract 445: Genomic characteristics and response to rucaparib and enzalutamide in the phase 1b RAMP study of metastatic castration-resistant prostate cancer (mCRPC) patients

2021 Cancer Research
Show All
- Source
- Cite
- Save
Citations (0)
688P Gene expression profiling (GEP) signatures associated with markers of sensitivity to immune and angiogenic therapy in clear-cell renal cell carcinoma (ccRCC) with sarcomatoid/rhabdoid features

2021 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (0)
A phase Ib trial of neoadjuvant/adjuvant durvalumab +/- tremelimumab in locally advanced renal cell carcinoma (RCC).

2020 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (1)